Megan Dauenhauer
Psychiatric/Mental Health · Metairie, LANPI 1871900464
Payments from drug & device makers
Across 215 payments — averaging $17.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$748
- Johnson & Johnson$473
- Alkermes, Inc.$430
- Teva Pharmaceuticals USA, Inc.$415
- Otsuka America Pharmaceutical, Inc.$382
- Neurocrine Biosciences, Inc.$297
- plus $910 from 9 others
What the payments were for
- Food & beverage$3,58198%
- Education$742%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 40 | $748 |
| Johnson & Johnson | 26 | $473 |
| Alkermes, Inc. | 29 | $430 |
| Teva Pharmaceuticals USA, Inc. | 31 | $415 |
| Otsuka America Pharmaceutical, Inc. | 23 | $382 |
| Neurocrine Biosciences, Inc. | 13 | $297 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 21 | $240 |
| Lundbeck LLC | 9 | $144 |
| Indivior Inc. | 5 | $124 |
| Vanda Pharmaceuticals Inc. | 5 | $121 |
| Axsome Therapeutics, Inc. | 5 | $102 |
| Supernus Pharmaceuticals, Inc. | 2 | $76 |
| E.r. Squibb & Sons, L.L.C. | 4 | $71 |
| Noven Therapeutics, LLC | 1 | $18 |
| Exact Sciences | 1 | $16 |
How this compares
$3,655 in reported general payments places this provider in the 75th percentile of 615 psychiatric/mental health providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 95 | $329,306 |
| Invega TrinzaPaliperidone Palmitate | 25 | $181,430 |
| Austedo XrDeutetrabenazine | 24 | $119,551 |
| Risperdal ConstaRisperidone Microspheres | 91 | $103,539 |
| VraylarCariprazine Hcl | 58 | $96,737 |
| Abilify AsimtufiiAripiprazole | 15 | $83,775 |
| LybalviOlanzapine/Samidorphan Malate | 18 | $30,987 |
| Risperidone ErRisperidone Microspheres | 21 | $20,761 |
| Aripiprazole | 234 | $9,819 |
| Paliperidone ErPaliperidone | 40 | $8,328 |
| Oxcarbazepine | 157 | $8,052 |
| Quetiapine Fumarate | 447 | $8,004 |
| Clozapine | 60 | $7,880 |
| Varenicline Tartrate | 15 | $6,677 |
| Effexor XrVenlafaxine Hcl | 12 | $6,162 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta | $473 | $614,275211 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $415 | $119,55124 claims |
| AbbVieVraylar | $748 | $96,73758 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Asimtufii | $382 | $83,77515 claims |
| Alkermes, Inc.Lybalvi | $430 | $30,98718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 615 psychiatric/mental health providers in Louisiana.
Other psychiatric/mental health in Metairie
- Marianne CallMetairie$12K
- Amy LacoutureBaton Rouge$663K
- Amanda EymardHouma$617K
- Amber LittlefieldBroussard$225K
- Timothy PellegrinHouma$210K
- Melissa GuilbeauLafayette$122K
- Kimberly ForcinelShreveport$92K
- Sattaria DilksLake Charles$57K
- Joe TaylorHammond$38K
- Lecy AlbaradoScott$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.